{"blog": [], "keywords": [{"value": "Mylan Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Teva Pharmaceutical Industries Ltd", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Perrigo Company", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/04/28/business/dealbook/mylan-rejects-tevas-40-billion-takeover-offer.html", "document_type": "article", "byline": {"person": [{"middlename": "J.", "firstname": "Michael", "role": "reported", "rank": 1, "lastname": "de la MERCED", "organization": ""}], "original": "By MICHAEL J. de la MERCED"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/04/28/business/28DB-DRUG/28DB-DRUG-thumbWide.jpg", "legacy": {"wide": "images/2015/04/28/business/28DB-DRUG/28DB-DRUG-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/04/28/business/28DB-DRUG/28DB-DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2015/04/28/business/28DB-DRUG/28DB-DRUG-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2015/04/28/business/28DB-DRUG/28DB-DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/04/28/business/28DB-DRUG/28DB-DRUG-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "736", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The move sets the stage for a fierce battle among three generic pharmaceutical giants.", "pub_date": "2015-04-28T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Mylan Rejects $40 Billion Takeover Bid by Teva in a Battle Over Generic Drugs", "main": "Mylan Rejects Teva\u2019s $40 Billion Takeover Offer"}, "print_page": "3", "snippet": "The move sets the stage for a fierce battle among three generic pharmaceutical giants.", "_id": "553e478238f0d8472d91b7a6", "slideshow_credits": null, "abstract": "Mylan rejects Teva takeover bid of $40 billion, setting up what may be drawn-out fight, even as Mylan pursues $33 billion takeover bid for Perrigo, which has so far been rejected."}